Lantern Pharma

LTRNNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$17.386 M

$1.36 -9.33%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$17.1M

Loss-making

Shares outstanding

12,784,146

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#404Allarity TherapeuticsALLR$17.7M
#405NewcelXNCEL$17.5M
#406Lantern PharmaLTRN$17.4M
#407BiofronteraBFRI$17.4M
#408Chemomab TherapeuticsCMMB$17.2M

What if Lantern Pharma were worth as much as…

Open the what-if tool →

Gold $30.2T

$2,364,958

Per share 1,738,940× higher

Bitcoin $1.74T

$136,235.54

Per share 100,173× higher

Nvidia $5.52T

$431,453.68

Per share 317,245× higher

Or at a round number

$50.0M $100.0M $200.0M $500.0M

Where these numbers come from

Share counts and financials for Lantern Pharma are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.